

Scancell

US IND for SCIB1 gives Phase II study the green light

3 February 2020

- Scancell has announced that the FDA has cleared the SCIB1 IND (Investigational New Drug) application. This means that both the UK and US arms of the Phase II trial, evaluating the SCIB1 vaccine in combination with the checkpoint inhibitor pembrolizumab (Keytruda) in metastatic melanoma, can now start.
- The US element of the trial had been delayed due to the FDA having a number of questions regarding [Ichor Medical Systems'](#) TriGrid v2.0 electroporation delivery device. This is a newer commercial version of the device that was employed in earlier clinical work. The resolution allows Scancell to initiate US site activities and patient enrolment, alongside UK clinical site expansion.
- The study will examine the tumour response rate, progression-free survival and overall survival in 25 patients with advanced melanoma. The aim is to explore if combination with a checkpoint inhibitor will improve treatment response with acceptable toxicities.
- Scancell's second ImmunoBody, SCIB2, uses a novel lipid nanoparticle formulation. The forthcoming CRUK-funded Phase I/II study will employ this via a standard injection, rather than using electroporation. Preclinical studies suggest the nanoparticle formulation is at least comparable to, and could be better than, using electroporation.

Trinity Delta view: ImmunoBody is the most clinically advanced of Scancell's three technology platforms. ImmunoBody vaccines have an elegant design that targets dendritic cells. They achieve efficient direct and cross-presentation of specific epitopes (peptide sequences from proteins), and a consistently strong anti-tumour immune response. Promising activity was seen in a SCIB1 monotherapy Phase I/II melanoma study, but the real potential, in our view, is in combination with checkpoint inhibitors. The FDA's green light for the US arm of the Phase II study is a welcome step forward and allows management to re-build momentum.

We maintain our valuation of £82.0m, equivalent to 17.2p a share. There are various likely catalysts over the coming year; including further AvidiMab collaborations, the SCIB1 UK trial being underway, and news flow on the timings of the first SCIB2 and Moditope clinical studies.

Price	6.55p
Market Cap	£30.5m
Primary exchange	AIM
Sector	Healthcare
Company Code	SCLP.L
Corporate client	Yes

Company description:

Scancell is a clinical-stage immuno-oncology specialist that has three technology platforms. Two flexible therapeutic vaccine platforms are progressing through development. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org

+44 (0) 20 3637 5043

Franco Gregori

fgregori@trinitydelta.org

+44 (0) 20 3637 5041

Mick Cooper

mcooper@trinitydelta.org
+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2020 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org